This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Clinical features of myelofibrosis include:

  • majority of the patients are over age 60 years at the time of diagnosis (1)
  • around 33% are asymptomatic at presentation (1)
  • progression is insidious - patients commonly present with fatigue and weakness due to anaemia; or because of abdominal fullness and early satiety due to splenomegaly
  • spleen is often massively enlarged -
  • is a characteristic finding (1)
  • seen in 90% of the patients at presentation (2)
  • can be massive in some patients (>10kg) (3)
  • symptoms include - pain, abdominal bloating, early satiety, difficulty with bending or routine activities or back pain due to altered centre of balance
  • splenic sequestration in splenomegaly may cause or exacerbate myelofibrosis associated cytopenias (3)
  • hepatomegaly occurs in over half of cases

With progressive fibrosis of bone marrow there may be:

  • severe anaemia - necessitating transfusion
  • bleeding - due to thrombocytopenia
  • respiratory pain - due to perisplenitis secondary to splenic infarction
  • severe bone pain, especially in the lower legs
  • hyperuricaemia and gout - from rapid blood cell turnover
  • cachexia

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.